Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 in Subjects With Pulmonary Arterial Hypertension
NCT04503733 is registered in ClinicalTrials.gov with Gmax Biopharm LLC. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-Controlled, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 in Subjects With Pulmonary Arterial Hypertension
- Lead sponsor
- Gmax Biopharm LLC.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- October 22, 2020
- Completion date
- June 10, 2023
- Enrollment
- 48 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.